SpacDeskBiotech & Pharma SPACs
5 active SPACs targeting Biotech & Pharma with $963.4M in trust.
The Biotech & Pharma sector currently accounts for five active SPACs, with four vehicles still searching for acquisition targets and one deal already announced. Aggregate capital deployed across the sector stands at $963.4 million, underscoring sustained institutional interest in life-sciences blank-check vehicles. A median days-to-expiration of 469 signals that the majority of these SPACs retain meaningful runway ahead of their respective deadlines, keeping the deal pipeline open for potential targets in drug development, medical technology, and adjacent life-sciences verticals. Investors and advisors tracking biotech SPAC activity can sign up at SpacDesk for full sponsor profiles, deal timelines, and real-time sector data.
| SPAC | Sponsor | Trust | Status | IPO Date | Target | Deadline |
|---|---|---|---|---|---|---|
| DMIIU Drugs Made In America Acquisition II Corp. | Drugs Made In America Acquisition LLC | $575.0M | Searching | 2025-09-25 | — | 2027-09-25 |
| DMAAR Drugs Made In America Acquisition Corp. | Drugs Made In America Acquisition LLC | $231.2M | Combo Announced | 2025-01-29 | Power Analytics Global Corp | 2026-04-29 |
| TKBD TechyBird Acquisition Corp. | TechyBird LLC | $60.3M | Searching | — | — | — |
| BCGF BCGF Acquisition Corp. | BCGH, LLC | $58.4M | Searching | — | — | — |
| CGRD GRD Biotechnology Acquisition Ltd | — | $38.6M | Searching | — | — | — |
Active = status not liquidated/closed/withdrawn. Trust size reflects declared trust at IPO. Industry classification based on sponsor focus area and target company sector.